AEQUALIS™ FLEX REVIVE™ Study (REVIVE) (REVIVE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05500066 |
Recruitment Status :
Enrolling by invitation
First Posted : August 12, 2022
Last Update Posted : February 20, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is an international, single arm, multicenter, prospective, non-significant risk, Post-Market Clinical Follow-up (PMCF) study. Data will be collected for the commercially available AEQUALIS FLEX REVIVE shoulder system in both the anatomic and reversed configurations.
The purpose of this study is to collect data needed to satisfy the European Union (EU) Medical Device Regulation (MDR) clinical post-market surveillance (PMS) and reporting requirements, and to support future regulatory submissions and peer-reviewed publications on device performance and safety.
Condition or disease | Intervention/treatment |
---|---|
Rheumatoid Arthritis Osteoarthritis Shoulder Fractures Humerus Avascular Necrosis Correction of Functional Deformity Traumatic Arthritis Revision of Other Devices if Sufficient Bone Stock Remains Rotator Cuff Tears | Device: Aequalis Flex Revive Shoulder System |
This is an international, single arm, multicenter, prospective, non-significant risk, Post-Market Clinical Follow-up (PMCF) study. Data will be collected for the commercially available AEQUALIS FLEX REVIVE shoulder system in both the anatomic and reversed configurations.
The primary outcome measure will be measured by the average improvement in American Shoulder and Elbow Surgeons (ASES) score from baseline to 24 months.
Secondary outcome measures include patient reported outcome measures (PROMs) and standard radiographic findings, including, but not limited to: device migration, component breakage, and bone characteristics.
Device revision and adverse events (AEs) will be assessed annually throughout the study. Range of motion and radiographic imaging assessments will also be performed at Years 1, 2, 5 and 10 post-operation.
Study Type : | Observational |
Estimated Enrollment : | 110 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | AEQUALIS™ FLEX REVIVE™ Study (REVIVE) |
Actual Study Start Date : | January 11, 2023 |
Estimated Primary Completion Date : | January 6, 2028 |
Estimated Study Completion Date : | January 3, 2036 |
Group/Cohort | Intervention/treatment |
---|---|
Aequalis Flex Revive Shoulder System
Commercially available shoulder system available in both anatomic and reversed configurations.
|
Device: Aequalis Flex Revive Shoulder System
The AEQUALIS FLEX REVIVE Shoulder System is intended for use as:
The system also allows for conversion from anatomic to reverse shoulder prosthesis in case of revision. |
- Average Improvement from Baseline to last follow-up visit in ASES Score [ Time Frame: 24 Month ]ASES Score = American Shoulder and Elbow Surgeons Score, 11 items with total score reported out of 100 measuring pain and activity of patient's evaluated shoulder where lower scores indicate more pain and less function
- Constant Score [ Time Frame: through study completion, an average of 1 year ]A score based on a 100-point scale determined by objective measurements made by the physician in the clinic and subjective values based on pain and activities of daily living reported by the patient.
- SANE [ Time Frame: through study completion, an average of 1 year ]Single question that asks the patient to rate their shoulder on a scale from 0 to 100, where 100 is normal.
- EQ 5-D [ Time Frame: through study completion, an average of 1 year ]Consists of a 5-question measure where patients rate their health today on a 5-point scale on a 5-dimension scale and a visual analogue scale to measure overall health status.
- Patient Satisfaction [ Time Frame: through study completion, an average of 1 year ]Single subjective question "How satisfied are you with your shoulder?"
- Radiographic Findings [ Time Frame: Baseline, 1 year, 2 year, 5 year and 10 year ]Images will be reviewed by a single orthopedic surgeon to assess for standard radiographic findings, including, but not limited to: device migration, component breakage, and bone characteristics.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- 18 years or older at the time of the informed consent.
- Informed and willing to sign an informed consent form approved by IRB or Ethics Committee (EC) (when applicable).
- Willing and able to comply with the requirements of the study protocol.
- Considered for a candidate for shoulder arthroplasty using the study device
- Meets indications for use requirements or other local, regional, or geographic specific regulatory requirements
Exclusion Criteria:
- Not able to comply with the study procedures based on the judgment of the assessor (e.g., cannot comprehend study questions, inability to keep scheduled assessment times)
- Patient belongs to a vulnerable group of patients, including minor patients, those unable to decide for themselves to participate or needing a Legally Authorized Representative (LAR), or others who could be subject to coercion (patients who may not be acting on their own initiative) (referred as "vulnerable subject" in the section 3.44 of the ISO 14155 norm).
- Active local or systemic infection, sepsis, or osteomyelitis
- Poor bone quality, where there could be considerable migration of the prothesis and/or a chance of fracture of the humerus or glenoid (reassessed at time of surgery)
- Significant injury to the brachial plexus
- Inadequate bone stock in the proximal humerus or glenoid fossa for supporting the components
- Neuromuscular disease (e.g., joint neuropathy)
- Patient with known allergy to one of the product materials
- Metabolic disorders which may impair bone formation
- Patient pregnancy
- Planned for two-stage surgery (reassessed at time of surgery)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05500066
United States, Colorado | |
Western Orthopaedics, P.C. | |
Denver, Colorado, United States, 80218 | |
United States, Florida | |
Coastal Orthopedics | |
Bradenton, Florida, United States, 34212 | |
Foundation for Orthopaedic Research & Education | |
Tampa, Florida, United States, 33637 | |
United States, Kentucky | |
Baptist Health Lexington | |
Lexington, Kentucky, United States, 40503 |
Study Director: | Arthur de Gast, MD MSc PhD | Stryker Trauma and Extremities |
Responsible Party: | Stryker Trauma GmbH |
ClinicalTrials.gov Identifier: | NCT05500066 |
Other Study ID Numbers: |
20F-W-REVIVE-RM |
First Posted: | August 12, 2022 Key Record Dates |
Last Update Posted: | February 20, 2024 |
Last Verified: | February 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | Yes |
Total Shoulder Replacement Osteoarthritis Joint Diseases Musculoskeletal Diseases |
Arthritis Osteoarthritis Necrosis Rotator Cuff Injuries Humeral Fractures Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |
Pathologic Processes Rupture Wounds and Injuries Shoulder Injuries Tendon Injuries Arm Injuries Fractures, Bone |